{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:27:24Z","timestamp":1786966044035,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperprolactinemia is a frequent clinical condition with different etiologies. Although primary hypothyroidism is often considered a leading cause of mild hyperprolactinemia, the supporting evidence is limited and often based on small studies with single prolactin (PRL) measurement, especially in cases of subclinical hypothyroidism. This study aims to evaluate the prevalence of thyroid dysfunction in patients assessed for functional hyperprolactinemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This retrospective study included patients undergoing cannulated PRL sampling (three measurements) and thyroid function assessment between January 2013 and May 2024, at Padova University-Hospital. Patients were stratified by PRL elevation and TSH levels. PRL-secreting pituitary adenoma and medication-induced hyperprolactinemia were exclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 292 patients with available data, 229 fulfilled the inclusion criteria. Hyperprolactinemia was confirmed in 89\/229 patients (39%). Among these, 26% had increased TSH compared to 16% in the normoprolactinemic group (p=0.083). PRL levels from cannulated samples and their mean values were not significantly higher in patients with hypothyroidism. No significant correlation was observed between TSH and PRL levels (Spearman\u2019s rho=0.053; p=0.428). The absence of association between TSH and PRL levels was confirmed also in a subgroup analysis in women of reproductive age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that subclinical hypothyroidism is common in patients evaluated for hyperprolactinemia: mild TSH increase should not delay the diagnostic evaluation for hyperprolactinemia, due to the low likelihood of thyroid dysfunction as the cause of hyperPRL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-026-03023-x","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:04:38Z","timestamp":1786964678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional hyperprolactinemia and subclinical primary hypothyroidism: myth or reality in clinical practice?"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7310-5078","authenticated-orcid":false,"given":"Giulia","family":"Bovo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9899-9328","authenticated-orcid":false,"given":"Pierluigi","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-5378","authenticated-orcid":false,"given":"Giorgia","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5727","authenticated-orcid":false,"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-8716","authenticated-orcid":false,"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4092-5107","authenticated-orcid":false,"given":"Irene","family":"Tizianel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"3023_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","volume":"37","author":"T Mancini","year":"2008","unstructured":"Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37:67\u201399","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3023_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0002-9378(72)90446-2","volume":"113","author":"JE Tyson","year":"1972","unstructured":"Tyson JE, Hwang P, Guyda H, Friesen HG (1972) Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 113:14\u201320","journal-title":"Am J Obstet Gynecol"},{"key":"3023_CR3","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.4088\/JCP.v65n1205","volume":"65","author":"M Misra","year":"2004","unstructured":"Misra M, Papakostas GI, Klibanski A (2004) Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 65:1607\u20131618","journal-title":"J Clin Psychiatry"},{"key":"3023_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/0004-2730000003002","volume":"58","author":"L Vilar","year":"2014","unstructured":"Vilar L, Fleseriu M, Bronstein MD (2014) Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq Bras Endocrinol Metabol 58:9\u201322","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"3023_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41574-023-00916-2","volume":"20","author":"S Petersenn","year":"2024","unstructured":"Petersenn S et al (2024) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 20:62\u201362","journal-title":"Nat Rev Endocrinol"},{"key":"3023_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1507\/endocrj.K10E-215","volume":"57","author":"Z Hekimsoy","year":"2010","unstructured":"Hekimsoy Z, Kafes\u00e7iler S, G\u00fc\u00e7l\u00fc F, \u00d6zmen B (2010) The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism. Endocr J 57:1011\u20131015","journal-title":"Endocr J"},{"key":"3023_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/0002-9343(78)90517-X","volume":"64","author":"KS Honbo","year":"1978","unstructured":"Honbo KS, Van Herle AJ, Kellett KA (1978) Serum prolactin levels in untreated primary hypothyroldism. Am J Med 64:782\u2013787","journal-title":"Am J Med"},{"key":"3023_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2265.2003.01694.x","volume":"58","author":"W Raber","year":"2003","unstructured":"Raber W, Gessl A, Nowotny P, Vierhapper H (2003) Hyperprolactinaemia in hypothyroidism: clinical significance and impact of TSH normalization. Clin Endocrinol (Oxf) 58:185\u2013191","journal-title":"Clin Endocrinol (Oxf)"},{"key":"3023_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1507\/endocrj.44.89","volume":"44","author":"K Notsu","year":"1997","unstructured":"Notsu K, Ito Y, Furuya H, Ohguni S, Kato Y (1997) Incidence of hyperprolactinemia in patients with Hashimoto\u2019s thyroiditis. Endocr J 44:89\u201394","journal-title":"Endocr J"},{"key":"3023_CR10","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1001\/archinte.1988.00380100122027","volume":"148","author":"KE Olive","year":"1988","unstructured":"Olive KE, Hennessey JV (1988) Marked hyperprolactinemia in subclinical hypothyroidism. Arch Intern Med 148:2278\u20132279","journal-title":"Arch Intern Med"},{"key":"3023_CR11","first-page":"229","volume":"2","author":"A Bahar","year":"2011","unstructured":"Bahar A, Akha O, Kashi Z, Vesgari Z (2011) Hyperprolactinemia in association with subclinical hypothyroidism. Caspian J Intern Med 2:229\u2013233","journal-title":"Caspian J Intern Med"},{"key":"3023_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-024-00214-7","volume":"18","author":"AA Khan","year":"2025","unstructured":"Khan AA et al (2025) Systematic review of the association between thyroid disorders and hyperprolactinemia. Thyroid Res 18:1","journal-title":"Thyroid Res"},{"key":"3023_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejim.2016.07.012","volume":"35","author":"LK Sharma","year":"2016","unstructured":"Sharma LK, Sharma N, Gadpayle AK, Dutta D (2016) Prevalence and predictors of hyperprolactinemia in subclinical hypothyroidism. Eur J Intern Med 35:106\u2013110","journal-title":"Eur J Intern Med"},{"key":"3023_CR14","unstructured":"Gosi SKY, Kaur J, Garla VV (2026) Subclinical Hypothyroidism"},{"key":"3023_CR15","doi-asserted-by":"crossref","unstructured":"Wyne KL et al (2023) hypothyroidism prevalence in the united states: a retrospective study combining national health and nutrition examination survey and claims data, 2009\u20132019. J. Endocr Soc 7","DOI":"10.1210\/jendso\/bvac172"},{"key":"3023_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nrc926","volume":"2","author":"SL Asa","year":"2002","unstructured":"Asa SL, Ezzat S (2002) The pathogenesis of pituitary tumours. Nat Rev Cancer 2:836\u2013849","journal-title":"Nat Rev Cancer"},{"key":"3023_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00035","volume":"7","author":"MS Ansari","year":"2016","unstructured":"Ansari MS, Almalki MH (2016) Primary hypothyroidism with markedly high prolactin. Front Endocrinol (Lausanne) 7:35","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3023_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1210\/jcem-37-3-488","volume":"37","author":"HE Carlson","year":"1973","unstructured":"Carlson HE, Jacob LS, Daughaday WH (1973) Growth hormone, thyrotropin and prolactin responses to thyrotropin-releasing hormone following diethylstilbestrol pretreatment*. J Clin Endocrinol Metab 37:488\u2013490","journal-title":"J Clin Endocrinol Metab"},{"key":"3023_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1210\/endo-115-1-407","volume":"115","author":"SM Foord","year":"1984","unstructured":"Foord SM et al (1984) Hypothyroid pituitary cells in culture: an analysis of thyrotropin and prolactin responses to dopamine (DA) and DA receptor binding*. Endocrinology 115:407\u2013415","journal-title":"Endocrinology"},{"key":"3023_CR20","first-page":"575","volume":"169","author":"O Serri","year":"2003","unstructured":"Serri O, Chik CL, Ur E, Ezzat S (2003) Diagnosis and management of hyperprolactinemia. CMAJ 169:575\u2013581","journal-title":"CMAJ"},{"key":"3023_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1677\/joe.0.1090359","volume":"109","author":"JRE Davis","year":"1986","unstructured":"Davis JRE, Lynam TC, Franklyn JA, Docherty K, Sheppard MC (1986) Tri-iodothyronine and phenytoin reduce prolactin messenger RNA levels in cultured rat pituitary cells. J Endocrinol 109:359\u2013364","journal-title":"J Endocrinol"},{"key":"3023_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1210\/endo-107-1-85","volume":"107","author":"WT Cave","year":"1980","unstructured":"Cave WT, Ann Paul M (1980) Effects of altered thyroid function on plasma prolactin clearance*. Endocrinology 107:85\u201391","journal-title":"Endocrinology"},{"key":"3023_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1089\/105072503322511391","volume":"13","author":"C Meier","year":"2003","unstructured":"Meier C et al (2003) Prolactin dysregulation in women with subclinical hypothyroidism: effect of levothyroxine replacement therapy. Thyroid 13:979\u2013985","journal-title":"Thyroid"},{"key":"3023_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2012546","volume":"2019","author":"P Shukla","year":"2019","unstructured":"Shukla P, Bulsara KR, Luthra P (2019) Pituitary hyperplasia in severe primary hypothyroidism: a case report and review of the literature. Case Rep Endocrinol 2019:1\u20137","journal-title":"Case Rep Endocrinol"},{"key":"3023_CR25","first-page":"1099","volume":"10","author":"AI Siddiqi","year":"2015","unstructured":"Siddiqi AI, Grieve J, Miszkiel K, Baldeweg SE (2015) Tablets or scalpel: pituitary hyperplasia due to primary hypothyroidism. Radiol Case Rep 10:1099","journal-title":"Radiol Case Rep"},{"key":"3023_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4158\/EP.12.1.29","volume":"12","author":"NM Khawaja","year":"2006","unstructured":"Khawaja NM et al (2006) Pituitary enlargement in patients with primary hypothyroidism. Endocr Pract 12:29\u201334","journal-title":"Endocr Pract"},{"key":"3023_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1210\/jcem-42-5-817","volume":"42","author":"T Yamada","year":"1976","unstructured":"Yamada T, Tsukui T, Ikejiri K, Yukimura Y, Kotani M (1976) Volume of sella turcica in normal subjects and in patients with primary hypothyroidism and hyperthyroidism. J Clin Endocrinol Metab 42:817\u2013822","journal-title":"J Clin Endocrinol Metab"},{"key":"3023_CR28","unstructured":"ISO 15189:2012 Medical laboratories\u2014Requirements for quality and competence. Published 2022.. https:\/\/www.iso.org\/standard\/56115.html. Accessed 10 April 2026"},{"key":"3023_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1210\/jcem-65-2-299","volume":"65","author":"ME Molitch","year":"1987","unstructured":"Molitch ME, Raiti S, Baumann G et al (1987) Pharmacokinetic studies of highly purified human prolactin in normal human subjects. J Clin Endocrinol Metab 65:299\u2013304. https:\/\/doi.org\/10.1210\/jcem-65-2-299","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03023-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-03023-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03023-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:04:44Z","timestamp":1786964684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-03023-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":29,"alternative-id":["3023"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-03023-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"18 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflicts of interest in this topic that might be perceived as influencing the impartiality of the reported research.","order":1,"name":"Ethics","label":"Competing of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}